OraSure Technologies (NASDAQ:OSUR) Downgraded by StockNews.com

StockNews.com lowered shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report sent to investors on Saturday.

A number of other research firms have also commented on OSUR. Evercore ISI raised their price target on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an in-line rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lowered their target price on shares of OraSure Technologies from $7.00 to $6.00 and set a neutral rating on the stock in a report on Monday, May 13th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, OraSure Technologies currently has an average rating of Hold and a consensus price target of $6.67.

OraSure Technologies Trading Up 2.2 %

NASDAQ:OSUR opened at $4.27 on Friday. The stock has a 50 day simple moving average of $4.28 and a 200 day simple moving average of $5.39. OraSure Technologies has a 1-year low of $3.91 and a 1-year high of $8.45. The stock has a market cap of $315.80 million, a P/E ratio of 14.23 and a beta of 0.09.

Institutional Investors Weigh In On OraSure Technologies

Several institutional investors and hedge funds have recently bought and sold shares of OSUR. AJOVista LLC bought a new position in OraSure Technologies in the 4th quarter valued at about $39,000. SG Americas Securities LLC bought a new position in OraSure Technologies in the first quarter valued at approximately $72,000. Mackenzie Financial Corp bought a new position in OraSure Technologies in the second quarter valued at approximately $72,000. Tocqueville Asset Management L.P. raised its position in OraSure Technologies by 20.0% during the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after purchasing an additional 2,512 shares in the last quarter. Finally, Shikiar Asset Management Inc. bought a new stake in OraSure Technologies during the second quarter worth $96,000. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.